Glaxosmithkline Intellectual Property Development Limited

Epizyme, Inc.

Glaxosmithkline LLC

Olena I Barbash

Richard Chesworth

Michael John Munchhof

Kenneth William Duncan

Lei Jin

Paula Ann Boriack-Sjodin

Elayne Penebre

Jacob Rubin

Andy Fedoriw

Niyant Shah

Jenny Laraio

Ping Zhang

Helai Mohammad

Ryan G Kruger

Sarah Gerhart

Shane W Obrien

Peter John Tummino

The present invention provides a combination of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The present invention also provides methods for treating cancer in a human in need thereof, the methods comprising administering to the human a combination of a Type I PRMT inhibitor and a Type II PRMT inhibitor, together with at least one of: a pharmaceutically acceptable carrier and a pharmaceutically acceptable diluent, thereby treating the cancer in the human. The present invention further provide a pharmaceutical composition comprising a therapeutically effective amount of a Type I PRMT inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a Type II PRMT inhibitor.

Combination therapy

Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.

PRMT5 inhibitors and uses thereof

Growing community of inventors

Collegeville, PA, United States of America

Olena I Barbash